Madrigal Pharmaceuticals (MDGL) vs Dr. Reddy's Laboratories (RDY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Madrigal Pharmaceuticals (MDGL) has outperformed Dr. Reddy's Laboratories (RDY) over the past year, gaining 11.8% versus a loss of 12.5%. Over five years, MDGL leads with a +466.0% price change compared with -7.1% for RDY. Madrigal Pharmaceuticals is the larger company by market cap ($11.27 billion vs $10.22 billion), about 1.1 times the size.
On valuation, Dr. Reddy's Laboratories trades at a lower forward P/E (19.0x vs 50.7x for Madrigal Pharmaceuticals). Dr. Reddy's Laboratories pays a dividend yielding 65.20%, while Madrigal Pharmaceuticals does not currently pay one. Dr. Reddy's Laboratories converts more of its revenue into profit, with a net margin of 17.4% versus -30.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDGL | RDY |
|---|---|---|
| Share price | $487.72 | $12.27 |
| Market cap | $11.27B | $10.22B |
| 1-day change | -1.76% | -1.76% |
| YTD return | -16.25% | -12.61% |
| 1-year return | +11.79% | -12.54% |
| 5-year return | +466.00% | -7.06% |
| P/E ratio (TTM) | — | 27.89 |
| Forward P/E | 50.67 | 19.04 |
| EPS (TTM) | $-12.85 | $0.44 |
| Dividend yield | 0.00% | 65.20% |
| Annual dividend | $0.00 | $8.00 |
| Revenue (latest FY) | $958.40M | $3.81B |
| Revenue growth (YoY) | +432.05% | +13.76% |
| Net income (latest FY) | $-288.28M | $663.00M |
| Gross margin | — | 58.51% |
| Operating margin | -31.31% | 22.09% |
| Net margin | -30.08% | 17.40% |
| 52-week high | $615.00 | $15.67 |
| 52-week low | $393.61 | $11.36 |
| Distance from 52-week high | -20.70% | -21.70% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +39.86% | +7.74% |
| Average volume | 292.63K | 2.92M |
| Shares outstanding | 23.10M | 832.99M |
| Employees | 915 | 27,527 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MDGL has outperformed RDY by 24.3 percentage points over the past year.
- Dr. Reddy's Laboratories offers a meaningfully higher dividend yield (65.20% vs 0.00%).
- Dr. Reddy's Laboratories is more profitable, keeping 17.4 cents of every revenue dollar as net income versus -30.1 cents for Madrigal Pharmaceuticals.
- Madrigal Pharmaceuticals grew revenue faster in its latest fiscal year (+432.05% vs +13.76%).
About Madrigal Pharmaceuticals
MDGL stock →Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees
About Dr. Reddy's Laboratories
RDY stock →Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 27,527 employees
MDGL vs RDY FAQ
Which is bigger, Madrigal Pharmaceuticals or Dr. Reddy's Laboratories?
Madrigal Pharmaceuticals (MDGL) is larger, with a market capitalization of $11.27B compared with $10.22B for Dr. Reddy's Laboratories (RDY).
Which stock has performed better over the past year, MDGL or RDY?
MDGL returned +11.79% over the past 12 months, compared with -12.54% for RDY (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Madrigal Pharmaceuticals or Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories pays a dividend yielding 65.20%, while Madrigal Pharmaceuticals does not currently pay a regular dividend.
Are Madrigal Pharmaceuticals and Dr. Reddy's Laboratories in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.